Plain-English translation of NCT06969924 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study examines how well cardiac resynchronization therapy works in adults who were born with heart defects. Researchers are looking at real patient records from 2014 onward to understand how this special pacemaker device affects heart function, patient symptoms, and overall quality of life in this population. By studying how the treatment actually performs in everyday practice, doctors hope to better understand who benefits most from this device.
Most information about this pacemaker therapy comes from patients with heart disease that developed later in life, not people born with heart defects. Adults with congenital heart disease often have unique heart structures and electrical patterns that may work differently with this treatment, so doctors need to study how well the therapy actually works in this specific group.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, meaning researchers will review your existing medical records — you won't need to attend visits or undergo new procedures. Researchers will collect information about your heart condition, details of your device implant, and how you've done since receiving the treatment. Your participation involves allowing the study team to access and analyze your health records to help improve care for future patients.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Netherlands
Sponsor
Leiden University Medical Center
Enrollment target
~100 participants
Started
January 2014
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anastasia D. Egorova, MD, PhD
Leiden University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.